印度的雌激素受体阴性乳腺癌：我们在这种亚型上的负担真的更重吗？
Estrogen Receptor Negative Breast Cancer in India: Do We Really Have Higher Burden of this Subtype?
作者信息
Manjunath Suraj, Prabhu Jyothi S, Kaluve Rohini, Correa Marjorie, Sridhar T S
出版信息
Indian J Surg Oncol. 2011 Jun;2(2):122-5. doi: 10.1007/s13193-011-0072-8. Epub 2011 May 31.
Abstract
ER negative and Triple negative breast cancers carry a poorer prognosis and are not amenable to hormone therapy. It has been previously observed that Indian patients with breast cancer have a higher tendency to have these tumours. Whether this is due to inherent biological differences in the tumours of our patients is a matter of much debate. We have analysed 250 patients of breast cancer for hormone receptor status, compared them with western series, and attempted to support the hypothesis that the higher ER negativity and triple negativity is indeed due to different tumour biology.
摘要
雌激素受体阴性和三阴性乳腺癌的预后较差，且不适合接受激素治疗。此前已有观察发现，印度乳腺癌患者患这些肿瘤的倾向更高。这是否归因于我们患者肿瘤中固有的生物学差异，是一个备受争议的问题。我们分析了250例乳腺癌患者的激素受体状态，将其与西方系列研究进行比较，并试图支持以下假设：雌激素受体阴性率和三阴性率较高确实是由于不同的肿瘤生物学特性所致。
相似文献
1
Estrogen Receptor Negative Breast Cancer in India: Do We Really Have Higher Burden of this Subtype?
Indian J Surg Oncol. 2011 Jun;2(2):122-5. doi: 10.1007/s13193-011-0072-8. Epub 2011 May 31.
2
ER-/PR+ breast cancer: A distinct entity, which is morphologically and molecularly close to triple-negative breast cancer.
Int J Cancer. 2021 Jul 1;149(1):200-213. doi: 10.1002/ijc.33539. Epub 2021 Mar 18.
3
Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in New Delhi, India.
Asian Pac J Cancer Prev. 2015;16(12):4959-64. doi: 10.7314/apjcp.2015.16.12.4959.
4
Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Cancer. 2008 Mar 1;112(5):995-1000. doi: 10.1002/cncr.23226.
5
Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010.
Breast. 2012 Jun;21(3):366-73. doi: 10.1016/j.breast.2012.03.004. Epub 2012 Apr 7.
6
Premorbid body weight and its relations to primary tumour diameter in breast cancer patients; its dependence on estrogen and progesteron receptor status.
Breast Cancer Res Treat. 2001 Jul;68(2):159-69. doi: 10.1023/a:1011977118921.
7
Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
World J Surg Oncol. 2016 Sep 13;14(1):244. doi: 10.1186/s12957-016-0999-x.
8
Identification of an immune-suppressed subtype of feline triple-negative basal-like invasive mammary carcinomas, spontaneous models of breast cancer.
Tumour Biol. 2020 Jan;42(1):1010428319901052. doi: 10.1177/1010428319901052.
9
Correlation of the value of 18F-FDG uptake, described by SUVmax, SUVavg, metabolic tumour volume and total lesion glycolysis, to clinicopathological prognostic factors and biological subtypes in breast cancer.
Nucl Med Commun. 2015 Jan;36(1):28-37. doi: 10.1097/MNM.0000000000000217.
10
Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience.
Indian J Med Paediatr Oncol. 2015 Apr-Jun;36(2):117-22. doi: 10.4103/0971-5851.158844.
引用本文的文献
1
Breast Carcinoma - A Comparative Study of Immunohistochemistry and Fluorescence in Situ Hybridization for Her-2 Assessment and Association of ER, PR, HER-2 and Ki-67 Expression with Clinico-Pathological Parameters.
Iran J Pathol. 2022 Fall;17(4):435-442. doi: 10.30699/IJP.2022.538167.2712. Epub 2022 Sep 2.
2
Clinicopathological Characteristics and Prognosis of Breast Cancer in Young Women - A Single Center Study in a Developing Country.
Cancer Manag Res. 2021 Feb 17;13:1601-1607. doi: 10.2147/CMAR.S299066. eCollection 2021.
3
Meta-Analysis of Prevalence of Triple-Negative Breast Cancer and Its Clinical Features at Incidence in Indian Patients With Breast Cancer.
JCO Glob Oncol. 2020 Jul;6:1052-1062. doi: 10.1200/GO.20.00054.
4
Low serum 25-hydroxy vitamin D levels are associated with aggressive breast cancer variants and poor prognostic factors in patients with breast carcinoma.
Arch Endocrinol Metab. 2018 Aug;62(4):452-459. doi: 10.20945/2359-3997000000062.
5
Patterns of Care of Breast Cancer Patients in a Rural Cancer Center in Western India.
Indian J Surg Oncol. 2018 Sep;9(3):374-380. doi: 10.1007/s13193-018-0748-4. Epub 2018 Apr 11.
6
Estrogen receptor, Progesterone receptor, and human epidermal growth factor receptor-2 status in breast cancer: A retrospective study of 5436 women from a regional cancer center in South India.
South Asian J Cancer. 2018 Jan-Mar;7(1):7-10. doi: 10.4103/sajc.sajc_211_17.
7
Improving accuracy of breast cancer biomarker testing in India.
Indian J Med Res. 2017 Oct;146(4):449-458. doi: 10.4103/ijmr.IJMR_896_16.
8
Hormone-receptor expression and survival patterns in operated cases of female invasive ductal breast carcinoma in Kerala: a retrospective cohort study.
World J Surg Oncol. 2015 Apr 23;13:160. doi: 10.1186/s12957-015-0582-x.
9
Preventing breast cancer in LMICs via screening and/or early detection: The real and the surreal.
World J Clin Oncol. 2014 Aug 10;5(3):509-19. doi: 10.5306/wjco.v5.i3.509.
10
Estrogen and progesterone receptor status in breast cancer: a cross-sectional study of 450 women in Kerala, South India.
World J Surg Oncol. 2014 Apr 24;12:120. doi: 10.1186/1477-7819-12-120.
本文引用的文献
1
Risk factors according to estrogen receptor status of breast cancer patients in Trivandrum, South India.
Int J Cancer. 2009 Oct 1;125(7):1663-70. doi: 10.1002/ijc.24460.
2
Hormone receptors over the last 8 years in a cancer referral center in India: what was and what is?
Indian J Pathol Microbiol. 2009 Apr-Jun;52(2):171-4. doi: 10.4103/0377-4929.48909.
3
Epidemiology and patterns of care for invasive breast carcinoma at a community hospital in Southern India.
World J Surg Oncol. 2007 May 23;5:56. doi: 10.1186/1477-7819-5-56.
4
High incidence of oestrogen receptor negative progesterone receptor positive phenotype in Indian breast cancer: fact or fiction?
Indian J Pathol Microbiol. 2005 Apr;48(2):199-201.
5
Clinical features and prognostic factors of early breast cancer at a major cancer center in North India.
Indian J Cancer. 2005 Jan-Mar;42(1):40-5. doi: 10.4103/0019-509x.15099.
6
Comparison of immunoexpression of 2 antibodies for estrogen receptors (1D5 and 6F11) in breast carcinomas using different antigen retrieval and detection methods.
Appl Immunohistochem Mol Morphol. 2004 Jun;12(2):177-82. doi: 10.1097/00129039-200406000-00014.
7
Immunohistochemical evaluation of hormone receptors in breast cancer: which scoring system is suitable for highly sensitive procedures?
Appl Immunohistochem Mol Morphol. 2004 Mar;12(1):8-13. doi: 10.1097/00129039-200403000-00002.
8
Hormone receptor status of breast cancer in India: a study of 798 tumours.
Breast. 2000 Oct;9(5):267-70; discussion 270. doi: 10.1054/brst.2000.0134.
9
Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma.
Am J Clin Pathol. 2003 Jul;120(1):86-92. doi: 10.1309/QPHD-RB00-QXGM-UQ9N.
10
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.
J Natl Cancer Inst. 2001 Jul 4;93(13):979-89. doi: 10.1093/jnci/93.13.979.
Zotero 插件